$71.96 -0.22 (%) Bristol-Myers Squibb Co - New York Stock Exchange, Inc.

May. 2, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Bristol-Myers Looks To A Promising Future

    Benzinga | Feb. 17, 2016 | 08:17AM EST
  2. Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark And More

    Benzinga | Feb. 14, 2016 | 14:09PM EST
  3. Intercept Pharma Spikes On Report That It’s Exploring A Sale

    IBD | Feb. 12, 2016 | 15:30PM EST
  4. Earnings Recap For January 28

    Benzinga | Jan. 28, 2016 | 16:34PM EST
  5. Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance

    Benzinga | Jan. 28, 2016 | 07:54AM EST
  6. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus | Jan. 26, 2016 | 14:59PM EST
  7. JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?

    Benzinga | Jan. 25, 2016 | 11:43AM EST
  8. Stock Marquee Crowded With Oil, Apple, and the Fed

    Benzinga | Jan. 25, 2016 | 10:25AM EST
  9. Benzinga's Top Downgrades

    Benzinga | Jan. 25, 2016 | 09:30AM EST
  10. Bristol-Myers Squibb's Opdivo + Yervoy Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

    Benzinga | Jan. 24, 2016 | 06:55AM EST
  11. Benzinga's Top Upgrades

    Benzinga | Jan. 22, 2016 | 08:50AM EST
  12. Fast Money Traders Share Their Biotech Picks

    Benzinga | Jan. 12, 2016 | 07:14AM EST
  13. Dual Therapeutics Announces Oncology Strategic Collaboration With Bristol-Myers Squibb

    GuruFocus | Jan. 8, 2016 | 23:04PM EST
  14. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD | Jan. 8, 2016 | 15:34PM EST
  15. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  16. Lilly Guidance Misses Estimates On Lower Sales

    IBD | Jan. 5, 2016 | 13:18PM EST
  17. Baxalta Cuts Cancer Deal As Shire Circles Nearer

    IBD | Jan. 4, 2016 | 12:52PM EST
  18. 5 Top Stocks of the Outperforming Vanguard Health Care Fund

    GuruFocus | Dec. 24, 2015 | 15:44PM EST
  19. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD | Dec. 18, 2015 | 14:05PM EST
  20. Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare for $350M Upfront Plus Milestone Payments

    Benzinga | Dec. 18, 2015 | 04:17AM EST
  21. Strategic Beta ETFs Among Year's Top Performers

    IBD | Dec. 15, 2015 | 19:12PM EST
  22. Fast Money Picks For December 15

    Benzinga | Dec. 15, 2015 | 07:18AM EST
  23. Signature Select Sells Stake in SPDR Gold Trust

    GuruFocus | Dec. 13, 2015 | 21:07PM EST
  24. Bristol-Myers Squibb CompanyNew Longer-Term Data for Empliciti Showed Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma #ASH2015

    Benzinga | Dec. 5, 2015 | 10:27AM EST
  25. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD | Dec. 4, 2015 | 13:46PM EST
  26. Bristol-Myers Squibb's

    IBD | Nov. 30, 2015 | 18:49PM EST
  27. Bristol-Myers Plans Projects

    IBD | Nov. 27, 2015 | 18:05PM EST
  28. Bristol-Myers Looks Beyond Cancer To Build Portfolio

    IBD | Nov. 27, 2015 | 08:02AM EST
  29. Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

    Benzinga | Nov. 24, 2015 | 06:55AM EST
  30. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD | Nov. 18, 2015 | 15:36PM EST
  31. Gilead Seen Staying Top Dog In HCV, But Merck Rising

    IBD | Nov. 18, 2015 | 12:10PM EST
  32. BRISTOL-MYERS SQUIBB'S

    IBD | Nov. 16, 2015 | 18:41PM EST
  33. Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?

    Benzinga | Nov. 9, 2015 | 09:03AM EST
  34. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD | Nov. 5, 2015 | 17:37PM EST
  35. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD | Nov. 5, 2015 | 12:23PM EST
  36. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD | Nov. 4, 2015 | 18:43PM EST
  37. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD | Nov. 3, 2015 | 18:43PM EST
  38. Bristol-Myers Squibb

    IBD | Oct. 27, 2015 | 18:46PM EST
  39. Gilead Outlook Disappoints

    IBD | Oct. 27, 2015 | 18:37PM EST
  40. 4 Drugmakers Who Beat Q3 Estimates Tuesday

    IBD | Oct. 27, 2015 | 12:30PM EST
  41. These Three Pharma Giants Just Crushed Earnings

    Benzinga | Oct. 27, 2015 | 10:09AM EST
  42. Earnings Scheduled For October 27, 2015

    Benzinga | Oct. 27, 2015 | 04:14AM EST
  43. Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And More

    Benzinga | Oct. 26, 2015 | 15:57PM EST
  44. Fed Meeting A Mid-Week Bump In Flurry Of Earnings News

    Benzinga | Oct. 26, 2015 | 14:02PM EST
  45. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD | Oct. 22, 2015 | 12:36PM EST
  46. Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment of Certain Patients with Chronic Hep C Genotypes 1, 3 and 4

    Benzinga | Oct. 15, 2015 | 19:37PM EST
  47. Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results

    Benzinga | Oct. 15, 2015 | 15:28PM EST
  48. Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher

    Benzinga | Oct. 15, 2015 | 12:25PM EST
  49. Benzinga's Volume Movers

    Benzinga | Oct. 15, 2015 | 10:46AM EST
  50. Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates

    Benzinga | Oct. 15, 2015 | 10:18AM EST
Trading Center